List of questions

Do you have any experience from having collaboration with the industry? If so, what kind of project and the outcome?

it is always talking a lot of the Swedish advantage regarding samples and registries and the possibility for the industry to use them, but so far no real time project has been presented. I am interested to hear if any conpany has done any eg biomarker research.

How can U-CAN be a partner for future development studies in Ph I-III?

New drugs directed at sub-populations of sub-populations are coming more and more. How can U-CAN serve to find patients for studies, does it cover a large anough geographical area, and what is attractive for the academia and the industry?

Can U-CAN be a fundament for structured introduction and health economical evaluation of new cancer drugs?

THere is a rising need for structured introduction of new drugs and evaluation of efficacy vs price and health economy. How can U-CAN be the optimal instrument for this?

How can pharma industry and academia cooperate around U-CAN for PASS-studies, prospective registries and academic studies? What exists in U-CAN and what is lacking?

More and more academic studies are being done with cooperative groups as sponsors. More PASS studies are being required from authorities to follow up new drugs. Is U-CAN a good instrument to start using for new such studies?

How can we use the UCAN biobank to identify biomarkers for Minimal Residual Disease in CLL? What new measurement tools and reagents are being used to increase measurement sensitivity and can be used to identify these biomarkers?

Even other cancer forms such as breast, lung and pancreatic cancer are of interest

In which areas of cancer research are the biggest needs for biomarker screening? e.g. Patient stratification, therapy selection etc.

a. Terapivägledning?
b. Patientstratifering?
c. Prediktion av tumöruppkomst?
d. Hur patienter svarar på behandling?
e. Annat?

Are there any specific tumor diagnoses where there is a particular need to screen for biomarkers?

What possibilities are there to carry out collaborative research projects and couple these to educational activities related to the launch of new diagnostics and predictive biomarkers?

na

What opportunities does UCAN provide for performing prospective studies?

na